Update in Food Allergy Management

Target Audience
This activity has been designed to address the educational needs of pediatric nurse practitioners, pediatricians, and allergists. It may also benefit other clinicians interested in the management of food allergy (FA).

Program Overview
New insights into the immunopathology of FA have led to development of cautious use of controlled exposure to food allergens through allergen immunotherapy and emerging use of monoclonal antibody therapy to interfere with the synthesis of immunoglobulin E (IgE). The expert faculty will contextualize the mechanisms and available clinical trial data related to the use of biologic agents in FA as monotherapy and as adjunct therapy to allergen immunotherapy.

Learning Objectives
Upon completion of this activity, participants should be able to:

Describe the burden of FA on children and caregivers
Describe the immunopathology of FA and related mechanisms by which biologic agents may mediate FA
Summarize clinical trial safety and efficacy data related to the use of anti-IgE therapy in FA (0.25 Rx)